Compare GSK plc (GSK) vs Jabil Inc (JBL) Price & Performance

GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.

The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.

JBL stock trades at $366.16, up 8.77% in the last session, reflecting strong momentum driven by AI infrastructure demand. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.16 exceeding the $3.10 forecast. Technical indicators show a bullish trend with the stock approaching resistance near $371, while fundamentals reveal solid revenue growth projections from $29.8B in 2025 to $33.6B in 2026.

JBL presents compelling growth potential as an AI infrastructure play with projected revenue exceeding $20B by 2027, though elevated P/E of 44.63 and thin net margins of 2.57% warrant caution. Analyst consensus targets $448.29 (22% upside) with balanced buy/hold ratings. Key risks include execution challenges in scaling AI operations and competitive pressures in electronics manufacturing services.